Aktieanalys

Xspray Pharma Q3 2024: Raising cash and anticipates H1 2025 launch of Dasynoc - Redeye

{newsItem.title}

Redeye Publicerad: 07 Nov 10:28

Redeye updates its valuation model following Xspray's announcement of SEK235m in financing and the company's Q3 report, which reaffirmed the anticipated timeline for Dasynoc and expected Q2 2025 NDA submission for XS003.

Länk till analysen i sin helhet: https://www.redeye.se/research/1049352/xspray-pharma-q3-2024-raising-cash-and-anticipates-h1-2025-launch-of-dasynoc?utm_source=finwire&utm_medium=RSS

Nyheter om Xspray Pharma

Läses av andra just nu

Om aktien Xspray Pharma

Senaste nytt